A new cell therapy for tough rheumatoid arthritis
Treatments studied
Part of Bones, joints & muscles, Immune system & allergy, Skin clinical trials.
This trial tests a cell therapy called UTAA91 for people with severe rheumatoid arthritis that hasn't improved with standard treatments. It aims to see if this approach can help when other options have failed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- Your rheumatoid arthritis is moderate to severe and has not responded to standard treatments.
- You are expected to live at least 3 more months.
- Your liver, kidneys, and heart need to be working well enough.
- You cannot have had certain cancer, active infections, or recent other treatments.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new injection called UTAA91 for people with hard-to-treat rheumatoid arthritis. It's for those who have tried standard treatments without success.
This trial tests a new type of immune cell therapy (CAR-T cells) designed to treat severe autoimmune rheumatic diseases like rheumatoid arthritis, lupus, or scleroderma that have not responded well to standard treatments. The therapy works by modifying your own immune cells to help control the disease.
This early-stage study tests a new injectable medicine (KT501) for people with moderate to severe rheumatoid arthritis who have not responded well enough to other treatments and have specific antibodies in their blood. It aims to see how safe and well-tolerated the drug is.
This trial tests a new medication called ADI-001 to see if it can help people with rheumatoid arthritis. It is for adults who meet the standard criteria for RA and are in generally good health otherwise.
This is an early-stage study testing a new injectable treatment called KT502 for people with moderate-to-severe rheumatoid arthritis (RA) that hasn't responded well to standard treatments. The study will check if the medication is safe and how the body responds to it.
This trial tests a new drug called telitacicept for people with rheumatoid arthritis (RA) that hasn't been controlled by multiple standard treatments. It aims to see if telitacicept can help reduce inflammation and improve symptoms.
Hear when a new Rheumatoid Arthritis (RA) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.